The dynamic landscape of Acute Coronary Syndrome (ACS) management has experienced significant advancements over the past decade. This article aims to provide a comprehensive overview of these advancements and best practices.
Advances in pharmacotherapy have been pivotal in ACS management. Novel antiplatelet agents such as Ticagrelor and Prasugrel have shown superior efficacy compared to traditional drugs, reducing the risk of recurrent ischemic events. Additionally, the advent of high-sensitivity cardiac troponin assays has improved early detection and risk stratification of ACS.
Early identification and risk stratification using the GRACE and TIMI risk scores remain crucial. Rapid initiation of dual antiplatelet therapy (DAPT) and anticoagulation therapy, followed by early invasive strategies (coronary angiography and revascularization), are recommended. High-risk patients benefit from early revascularization, while conservative strategies may be suitable for low-risk patients.
Cardiac rehabilitation plays a significant role in secondary prevention. It includes patient education, exercise training, diet counseling, and psychosocial support. Participation in cardiac rehabilitation programs has been associated with improved outcomes and reduced mortality in ACS patients.
Future research should focus on refining risk stratification tools, developing novel therapeutic agents, and optimizing the timing and selection of invasive strategies. Personalized medicine, considering genetics and comorbidities, will play an increasing role in ACS management.
Effective management of ACS requires a multifaceted approach, encompassing rapid diagnosis, risk stratification, prompt initiation of therapy, and comprehensive cardiac rehabilitation. The integration of recent advancements into clinical practice, coupled with adherence to evidence-based guidelines, will ensure optimal patient outcomes in ACS.
1.
New Nanoparticles Can Destroy Undruggable Cancer Proteins
2.
Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer
3.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
4.
Belzutifan Plus Pembro Approved for Adjuvant RCC
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
2.
Obesity as a major risk factor for cancer
3.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
4.
Advanced Pathways in Oncology for Better Care
5.
Essential Updates in Hematology in Daily Practice
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Understanding Anemia and Its Common Causes
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Early Cancer Detection Saves Lives
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation